Insights into Third-Line Treatment Selection for Patients with EGFR Exon 20-mutated mNSCLC

Video

Experts consider how they might approach third-line treatment selection for patients with EGFR exon 20-mutated mNSCLC who experience disease progression on amivantamab or other second-line therapies.

Newsletter

Stay up to date on practice-changing data in community practice.

Recent Videos
2 experts in this video
2 experts in this video
2 experts in this video
2 experts in this video
2 experts in this video
2 experts in this video
2 experts in this video
2 experts in this video
Related Content